An EMD Serono drug designed to treat lung cancer driven by a rare genetic alteration is now approved by the FDA, joining a growing list of targeted cancer therapies. The FDA announced the decision for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback